|
2018 Journal Article Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaMartin, Andrew J., Gibbs, Emma, Sjoquist, Katrin, Pavlakis, Nick, Simes, John, Price, Tim, Shannon, Jenny, Gill, Sanjeev, Jain, Vikram, Liu, Geoffrey, Kannourakis, George, Kim, Yeul Hong, Kim, Jin Won and Goldstein, David (2018). Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer, 21 (3), 473-480. doi: 10.1007/s10120-017-0754-1 |
|
2018 Journal Article Optimizing live kidney donor workup: A decision analysis approachCheng, Jian Y., Martin, Andrew, Ramanathan, Ganesh and Cooper, Bruce A. (2018). Optimizing live kidney donor workup: A decision analysis approach. Transplantation Direct, 4 (5) e340, 5. doi: 10.1097/TXD.0000000000000777 |
|
2018 Journal Article Effect of three- vs four-dimensional ultrasonography on maternal attachmentBenzie, R. J., Starcevic, V., Viswasam, K., Kennedy, N. J., Mein, B. J., Wye, D. A. and Martin, A. (2018). Effect of three- vs four-dimensional ultrasonography on maternal attachment. Ultrasound in Obstetrics and Gynecology, 51 (4), 558-559. doi: 10.1002/uog.17567 |
|
2018 Journal Article Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: What makes it worthwhile?Blinman, P. L., Davis, I. D., Martin, A., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., Eisen, T. and Stockler, M. R. (2018). Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: What makes it worthwhile?. Annals of Oncology, 29 (2), 370-376. doi: 10.1093/annonc/mdx715 |
|
2018 Journal Article How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologistsMoth, E. B., Kiely, B. E., Naganathan, V., Martin, A. and Blinman, P. (2018). How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists. Supportive Care in Cancer, 26 (2), 451-460. doi: 10.1007/s00520-017-3843-0 |
|
2018 Journal Article What survival benefits are needed to make adjuvant sorafenib worthwhile after resection of intermediate- or high-risk renal cell carcinoma? Clinical investigators' preferences in the SORCE trialLawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair, Meade, Angela, Eisen, Tim, Blinman, Prunella and Stockler, Martin R. (2018). What survival benefits are needed to make adjuvant sorafenib worthwhile after resection of intermediate- or high-risk renal cell carcinoma? Clinical investigators' preferences in the SORCE trial. Kidney Cancer, 2 (2), 123-131. doi: 10.3233/KCA-180038 |
|
2017 Conference Publication Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric CancerVasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Snow, Stephanie, Jonker, Derek, Chua, Yu Jo, Epstein, Richard, Bonaventura, Tony, Khasraw, Mustafa, Varma, Suresh, Singhal, Nimit, Ransom, David, Aubin, Francine, Burkes, Ronald, Lim, Howard, Lemay, Frederic, Begbie, Stephen, Stockler, Martin and Kiely, Belinda (2017). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCTYee, Jasmine, Davis, Glen M., Hackett, Daniel, Beith, Janem M., Wilcken, Nicholas, Currow, David, Emery, Jon, Phillips, Jane, Martin, Andrew, Hui, Rina, Harrison, Michelle, Segelov, Eva and Kilbreath, Sharon L. (2017). Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCT. HOBOKEN: WILEY. |
|
2017 Conference Publication P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)Wong, Nicole, Nayar, Namrata, Lawrence, Nicola, Stockler, Martin, Martin, Andrew, Yip, Sonia, Yeung, Annie, Friedlander, Michael, Mazhar, Danish, Pashankar, Farzana, Quinn, David, Walker, Roderick, Winstanley, Mark, Weickhardt, Andrew, Hanning, Fritha, Stevanovic, Amanda, Davis, Ian, Toner, Guy and Grimison, Peter (2017). P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS). HOBOKEN: WILEY. |
|
2017 Conference Publication Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?Vasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Goldstein, David, Shapiro, Jeremy, Karapetis, Chris, Gill, Sanjeev, Jain, Vikram, Liu, Geoffrey, Kannourakis, George, Kim, Yeul Hong, Wigston (Nott), Louise, Snow, Stephanie, Harris, Dean, Jonker, Derek, Chua, Yu Jo, Stockler, Martin and Kiely, Belinda (2017). Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?. HOBOKEN: WILEY. |
|
2017 Conference Publication The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung CancerEmery, Jon, Murray, Sonya, Campbell, Neil, Walter, Fiiona M., Mazza, Danielle, Habgood, Emily, Kutzer, Yvonne, Martin, Andrew, Goodall, Stephen, Barnes, David and Murchie, Peter (2017). The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of ToxicityMoth, Erin B., Kiely, Belinda E., Naganathan, Vasikaran, Martin, Andrew, Stefanic, Natalie, Beale, Philip, Grimison, Peter and Blinman, Prunella (2017). Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of Toxicity. HOBOKEN: WILEY. |
|
2017 Journal Article SCORE: Shared care of Colorectal cancer survivors: Protocol for a randomised controlled trialJefford, Michael, Emery, Jon, Grunfeld, Eva, Martin, Andrew, Rodger, Paula, Murray, Alexandra M., De Abreu Lourenco, Richard, Heriot, Alexander, Phipps-Nelson, Jo, Guccione, Lisa, King, Dorothy, Lisy, Karolina, Tebbutt, Niall, Burgess, Adele, Faragher, Ian, Woods, Rodney and Schofield, Penelope (2017). SCORE: Shared care of Colorectal cancer survivors: Protocol for a randomised controlled trial. Trials, 18 (1) 506, 1-10. doi: 10.1186/s13063-017-2245-4 |
|
2017 Journal Article Pelvic organ support several years after a first birthFerreira, Caroline W. S., Atan, Ixora K., Martin, Andrew, Shek, Ka Lai and Dietz, Hans Peter (2017). Pelvic organ support several years after a first birth. International Urogynecology Journal, 28 (10), 1499-1505. doi: 10.1007/s00192-017-3297-4 |
|
2017 Conference Publication Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trialLawrence, N. J., Martin, A., Davis, I. D., Troon, S., Sengupta, S., Hovey, E. J., Coskinas, X., Kaplan, R., Ritchie, A. W. S., Meade, A., Eisen, T., Blinman, P. and Stockler, M. R. (2017). Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancerVasista, A., Martin, A., Pavlakis, N., Sjoquist, K., Snow, S., Jonker, D., Chua, Y. J., Epstein, R., Bonaventura, A., Khasraw, M., Varma, S. C., Singhal, N., Ransom, D. T., Aubin, F., Burkes, R., Lim, H., Lemay, F., Begbie, S., Stockler, M. R. and Kiely, B. (2017). Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Journal Article Risk of tuberculosis in patients with solid cancers and haematological malignancies: A systematic review and meta-analysisDobler, Claudia C., Cheung, Kelvin, Nguyen, John and Martin, Andrew (2017). Risk of tuberculosis in patients with solid cancers and haematological malignancies: A systematic review and meta-analysis. European Respiratory Journal, 50 (2) 1700157, 1700157. doi: 10.1183/13993003.00157-2017 |
|
2017 Conference Publication Predicted Benefits of Adjuvant Sorafenib After Nephrectomy for Renal Cell Carcinoma (RCC) in SORCE: An International, Placebo-Controlled, Randomized Phase 3 TrialLawrence, N., Martin, A., Davis, I. D., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., Eisen, T., Blinman, P. and Stockler, M. (2017). Predicted Benefits of Adjuvant Sorafenib After Nephrectomy for Renal Cell Carcinoma (RCC) in SORCE: An International, Placebo-Controlled, Randomized Phase 3 Trial. HOBOKEN: WILEY. |
|
2017 Journal Article Experimental modeling of an air-gap membrane distillation module and simulation of a solar thermal integrated system for water purificationKumar, N. T. Uday and Martin, Andrew (2017). Experimental modeling of an air-gap membrane distillation module and simulation of a solar thermal integrated system for water purification. Desalination and Water Treatment, 84, 123-134. doi: 10.5004/dwt.2017.21201 |
|
2017 Conference Publication USING TRIAL INFRASTRUCTURE EFFICIENTLY: PLATFORM, FACTORIAL, AND UMBRELLA TRIAL DESIGNSMartin, Andrew (2017). USING TRIAL INFRASTRUCTURE EFFICIENTLY: PLATFORM, FACTORIAL, AND UMBRELLA TRIAL DESIGNS. HOBOKEN: WILEY. |
